- Trials with a EudraCT protocol (692)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (10)
692 result(s) found for: Metabolites.
Displaying page 1 of 35.
EudraCT Number: 2005-004299-19 | Sponsor Protocol Number: 1A/8655-5 | Start Date*: 2005-10-26 |
Sponsor Name:University Hospital Ostrava | ||
Full Title: New Possibilities of TDM of Cyclosporine A and its metabolites after kidney transplantation | ||
Medical condition: patient on standart immunusupresive therapy with cyclosporine A after renal transplantation | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: CZ (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2006-005809-65 | Sponsor Protocol Number: UA12 | Start Date*: 2006-12-20 |
Sponsor Name:Department of pharmacy, Uppsala University | ||
Full Title: An open, fixed order, single center pharmacokinetic study of the influence of St John's wort on the pharmacokinetics and metabolism of fiansteride in healthy male subjects | ||
Medical condition: The trial contains only healthy volunteers. The indication for Proscar is benign prostatic hyperplasia and for Movina mild depression. | ||
Disease: | ||
Population Age: Adults | Gender: Male | |
Trial protocol: SE (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2019-003959-11 | Sponsor Protocol Number: 1703001 | Start Date*: 2020-05-25 |
Sponsor Name:Vestre Viken Trust | ||
Full Title: MUscle Side-Effects of atorvastatin in coronary patients (MUSE) follow-up study | ||
Medical condition: Coronary heart disease patients With perceived statin Associated muscle symptoms or statin discontinuaton due to muscle symptoms | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NO (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2018-001711-67 | Sponsor Protocol Number: VX18-659-106 | Start Date*: 2019-08-21 | |||||||||||
Sponsor Name:Vertex Pharmaceuticals Incorporated | |||||||||||||
Full Title: A Phase 3 Study Evaluating the Pharmacokinetics, Safety, and Tolerability of VX-659/TEZ/IVA Triple Combination Therapy in Cystic Fibrosis Subjects 6 Through 11 Years of Age | |||||||||||||
Medical condition: Cystic fibrosis | |||||||||||||
|
|||||||||||||
Population Age: Children, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: Outside EU/EEA | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-001004-33 | Sponsor Protocol Number: VX15-809-115 | Start Date*: 2018-01-10 | |||||||||||
Sponsor Name:Vertex Pharmaceuticals Incorporated | |||||||||||||
Full Title: A Phase 3, 2-Part, Open-label Study to Evaluate the Safety and Pharmacokinetics of Lumacaftor/Ivacaftor Combination Therapy in Subjects Aged 2 Through 5 Years With Cystic Fibrosis, Homozygous for t... | |||||||||||||
Medical condition: Cystic Fibrosis | |||||||||||||
|
|||||||||||||
Population Age: Children, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: Outside EU/EEA | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-004979-39 | Sponsor Protocol Number: MSP-2017-1220 | Start Date*: 2020-08-06 |
Sponsor Name:Milestone Pharmaceuticals Inc. | ||
Full Title: An open-label, mass balance study to investigate the absorption, distribution, metabolism and excretion of [14C]-etripamil nasal spray after a single dose to healthy male subjects | ||
Medical condition: Paroxysmal supraventricular tachycardia (PSVT) | ||
Disease: | ||
Population Age: Adults | Gender: Male | |
Trial protocol: NL (Completed) | ||
Trial results: View results |
EudraCT Number: 2013-002720-16 | Sponsor Protocol Number: CPPM2013 | Start Date*: 2014-10-08 |
Sponsor Name:Stockholms Läns Sjukvårdsområde (SLSO) | ||
Full Title: EMPHAS I Evaluation of Methylphenidate (MPH) in adults with ADHD and SUD - clinical pharmacology study A Cross-sectional, Open-label, Non-randomized Single-Center Study on Adults with ADHD and ... | ||
Medical condition: ADHD | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: SE (Completed) | ||
Trial results: View results |
EudraCT Number: 2019-002539-27 | Sponsor Protocol Number: IntraRenalTac | Start Date*: 2019-09-23 | |||||||||||
Sponsor Name:Oslo University Hospital – Rikshospitalet | |||||||||||||
Full Title: Association between intrarenal tacrolimus concentration and development of renal interstitial fibrosis in renal transplant recipients | |||||||||||||
Medical condition: Development of renal interstitial fibrosis in renal transplant recipients | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NO (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-000956-32 | Sponsor Protocol Number: 20022012 | Start Date*: 2012-06-28 |
Sponsor Name:St. Antonius Ziekenhuis | ||
Full Title: Pharmacokinetics of intravenous acetaminophen and its metabolites in morbidly obese patients | ||
Medical condition: Morbid obesity | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: NL (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2018-002529-48 | Sponsor Protocol Number: WADA2018vil | Start Date*: 2018-09-12 | |||||||||||
Sponsor Name:Center for Aktiv Sundhed, Rigshospitalet | |||||||||||||
Full Title: Urine concentrations of vilanterol after inhaled administration of vilanterol/fluticasone furoate: Defining a urine threshold and decision limit for vilanterol in doping control analysis | |||||||||||||
Medical condition: Pharmacokinetics of vilanterol in relation to doping analysis | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-002588-24 | Sponsor Protocol Number: CLEE011A2201 | Start Date*: 2013-12-30 |
Sponsor Name:Novartis Pharma AG | ||
Full Title: A randomized pre-surgical pharmacodynamics study to assess the biological activity of LEE011 plus letrozole versus single agent letrozole in primary breast cancer | ||
Medical condition: HR+, HER2- early breast cancer | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Female | |
Trial protocol: NL (Completed) ES (Prematurely Ended) FR (Completed) | ||
Trial results: View results |
EudraCT Number: 2014-000537-24 | Sponsor Protocol Number: IIS-HEPA-TEST | Start Date*: 2014-07-16 |
Sponsor Name:INSTITUTO DE INVESTIGACION SANITARIA LA FE | ||
Full Title: Pilot clinical trial phase I / IIa to determine condition, low dose and effectiveness of liver function tests (Hepatotest) | ||
Medical condition: Hepatic Function. | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: ES (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2014-002481-78 | Sponsor Protocol Number: EBI-EA230-LPS-2014 | Start Date*: 2014-10-07 |
Sponsor Name:Exponential Biotherapies Inc | ||
Full Title: Randomized double blind placebo-controlled clinical safety, tolerability and pharmacokinetic/-dynamic study on the effects of escalating single intravenous doses of EA-230 on the innate immune resp... | ||
Medical condition: Systemic inflammatory respons (SIRS) and associated acute kidney injury (AKI) | ||
Disease: | ||
Population Age: Adults | Gender: Male | |
Trial protocol: NL (Completed) | ||
Trial results: View results |
EudraCT Number: 2012-005299-32 | Sponsor Protocol Number: OPHT-110912 | Start Date*: 2013-01-24 | |||||||||||
Sponsor Name:Medizinische Universität Wien, Universitätsklinik für Klinische Pharmakologie | |||||||||||||
Full Title: Effect of breathing 100% oxygen on brain metabolites measured by 7-Tesla MRI | |||||||||||||
Medical condition: brain metabolism | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: AT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-005124-24 | Sponsor Protocol Number: 6378707817 | Start Date*: 2018-01-31 |
Sponsor Name:Erasmus MC Cancer Institute | ||
Full Title: Therapeutic Drug Monitoring guided tamoxifen dosing: a feasibility study in patients with hormone positive breast cancer | ||
Medical condition: Hormone positive breast cancer | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Female | |
Trial protocol: NL (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2006-004578-29 | Sponsor Protocol Number: P.sitsen.01 | Start Date*: 2007-06-15 |
Sponsor Name:Leids Universitair Medisch Centrum | ||
Full Title: The efficacy of intravenous versus rectal paracetamol: A randomized, prospective, double-blind placebo-controlled study | ||
Medical condition: Aims of the study 1)to compare the analgesic efficacy of intravenous versus rectal paracetamol versus placebo as assessed by VAS scores and PCA morphine consumption. 2)To assess the pharmacokinet... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2017-002898-19 | Sponsor Protocol Number: IndiviStat#1 | Start Date*: 2018-01-08 |
Sponsor Name:Helsinki University Central Hospital | ||
Full Title: There is no English name for the trial. | ||
Medical condition: Primary prevention of atherosclerotic disease | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: FI (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2019-002020-33 | Sponsor Protocol Number: OZBS32.18194 | Start Date*: 2019-12-10 | |||||||||||
Sponsor Name:Erasmus University Medical Center | |||||||||||||
Full Title: Pentoxifylline dose optimization in neonatal sepsis. | |||||||||||||
Medical condition: Neonatal late onset sepsis | |||||||||||||
|
|||||||||||||
Population Age: Preterm newborn infants, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Ongoing) PL (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-004011-44 | Sponsor Protocol Number: UofATURRIFIC | Start Date*: 2020-05-20 |
Sponsor Name:The University of Adelaide | ||
Full Title: A randomised trial of URsodeoxycholic acid versus RIFampicin in severe early onset Intrahepatic Cholestasis of pregnancy: the TURRIFIC study, comparing their effectiveness in the reduction of pruri... | ||
Medical condition: Intrahepatic Cholestasis of Pregnancy (ICP) is an serious liver condition in pregnancy. The main symptom of this is itching. Ursodeoxycholic acid is routinely used to treat cholestasis but is not... | ||
Disease: | ||
Population Age: Adults | Gender: Female | |
Trial protocol: FI (Completed) GB (GB - no longer in EU/EEA) SE (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2014-001197-34 | Sponsor Protocol Number: 200942 | Start Date*: 2014-11-05 | |||||||||||
Sponsor Name:GlaxoSmithKline Research & Development Ltd | |||||||||||||
Full Title: A repeat-dose, open-label, parallel-group study to assess the pharmacokinetics of GSK1278863 and metabolites in subjects with End Stage Renal Disease undergoing peritoneal dialysis. | |||||||||||||
Medical condition: Anemia associated with chronic kidney disease (CKD) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
